Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AbbVie Deutschland GmbH & Co. KG
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
Study to Compare ABT-494 to Abatacept in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-CHOICE)
1. To compare the safety and efficacy of ABT-494 versus abatacept intravenous (IV) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDM...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE)
To compare a treat-to-target (T2T) intense treatment approach with a routine treatment approach (Standard of Care [SOC]) in reducing disease activity at week 32 in patients with axial spondyloarthriti...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB
To evaluate the efficacy of GDC-0199 and rituximab (GDC-0199+R) compared with bendamustine and rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) as measured by ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate
The primary objectives are to compare the efficacy of ABT-122 versus placebo in subjects on background methotrexate (MTX) as assessed by ACR20 at Week 12 and to assess the safety and tolerability of A...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis
To evaluate the Long-Term Safety and Efficacy of ABT-494
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma
The primary objective of study is to assess if the addition of ABT-888 to temozolomide (TMZ) can prolong Progression Free Survival (PFS) compared to TMZ alone in subjects with metastatic melanoma (MM)...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A long term extension trial of BI 655066/ABBV-066 (risankizumab) in patients with moderately to severely active Crohn's disease
To investigate long-term safety of BI 655066/ABBV-066 (risankizumab), in patients with moderately to severely active Crohn`s disease, who showed a clinical response or remission on previous treatment ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis
To demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Estudio en fase II, aleatorizado, enmascarado, multicéntrico y comparativo entre veliparib más FOLFIRI ± bevacizumab frente a placebo más FOLFIRI ± bevacizumab en el cáncer colorrectal metastásico previamente no tratado
The primary objectives of the study is to assess whether the addition of oral veliparib to FOLFIRI will improve progression-free survival (PFS) in subjects with metastatic colorectal cancer (mCRC). ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory or previously untreated Chronic Lymphocytic Leukemia with the 17p Deletion
Main Cohort Primary Objective: To evaluate the efficacy of venetoclax monotherapy in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. Efficacy will ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant